Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 293-296

  Shimoda, Kazutaka ^a   Someya, Toshiyuki ^c   Morita, Sachiyo ^a   Hirokane, Genta ^a   Noguchi, Toshifumi ^d   Yokono, Aya ^a   Shibasaki, Morikazu ^e   Takahashi, Saburo ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b The University of Shiga Prefecture   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

^d Psychiatry Service   (Japan)

^e Saitama Kounan Hospital   (Japan)

Author keywords

Haloperidol; Plasma levels; Smoking

Indexed keywords

HALOPERIDOL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEALKYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME IMMUNOASSAY; ENZYME INDUCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REDUCTION; SCHIZOPHRENIA; SMOKING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPSYCHOTIC AGENTS; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SMOKING;

EID: 0033007984     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00006     Document Type: Article

References (25)

1. Japan Tobacco Co., Ltd. The survey of smokers in Japan: 1998.
2. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-7.
3. Jusko WJ. Influence of cigarette smoking on drug metabolism in man. Drug Memb Rev 1979;9:221-8.
4. Dawson GW, Vestal RE. Smoking and drug metabolism. Pharmacol Ther 1982;15:207-21.
5. Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet 1989;17:90-108.
6. Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983; 44:420-2.
7. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985;20:329-32.
8. Pantuck EJ, Pantuck CB, Anderson KE, Conney AH, Kappas A. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 1982;31:533-8.
9. Jann MW, Saklad SR, Ereshefsky L, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmocology 1986;90:468-70.
10. Miller DD, Kelly MW, Perry PJ, Coryell WH. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990;28:529-31.
11. Tsuneizumi T, Aoba A, Yamaguchi N, et al. The effect of smoking on plasma neuroleptic levels of haloperidol and chlorpromazine. St Marianna Med J 1990;18:298-305.
12. Perry PJ, Miller DD, Arndt SV, Smith DA, Holman TL. Haloperidol dosing requirements: The contribution of smoking and non-linear pharmacokinetics. J Clin Psychopharmacol 1993;13:46-51.
13. Midha KK, Chakraborty BS, Ganes DA, et al. Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 1989;9:98-104.
14. Dysken MW, Kim SW, Vatassery G, et al. Haloperidol decanoate pharmacokinetics in red blood cells and plasma. J Clin Psychopharmacot 1992;12:128-32.
15. The American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Fourth edition. Washington, D.C.: The American Psychiatric Association, 1994.
16. Morita S, Someya T, Hirokane G, et al. Effect of aging on blood levels of haloperidol. Jpn J Psychiatr Treat 1997;12:423-8.
17. Usuki E, Pearce R, Parkinson A, Castagnol NJ. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes. Chem Res Toxicol 1996;9:800-6.
18. Pan LP, Wijnant P, De Vriendt C, Rosseel MT, Belpaire FM. Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol. Br J Clin Pharmacol 1997;44:557-64.
19. Inaba T, Kovacs J. Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 1989;17:330-3.
20. Young D, Midha KK, Fossler MJ, et al. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implication for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993;44:433-8.
21. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992;14:261-4.
22. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y. Use of antisera in the isolation of human specific conjugate of haloperidol. Xenobiotica 1989;19:781-93.
23. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
24. Daniel DG, Randolph C, Jaskiw G, et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994;14:340-3.
25. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: Interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31: 347-53.